Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies

References

• Yamamoto-FurushoJKPodolskyDKInnate immunity in inflammatory bowel diseaseWorld J Gastroenterol2007135577558017948931
   PubMed Web of Science ®Google Scholar
• BernsteinCNShanahanFDisorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseasesGut20085791185119118515412
   PubMed Web of Science ®Google Scholar
• GohKXiaoSDInflammatory bowel disease: a survey of the epidemiology in AsiaJ Dig Dis2009101619236540
   PubMed Web of Science ®Google Scholar
• TorresEADe JesúsRPérezCMPrevalence of inflammatory bowel disease in an insured population in Puerto Rico during 1996P R Health Sci J20032225325814619451
   PubMedGoogle Scholar
• Yamamoto-FurushoJKClinical epidemiology of ulcerative colitis in Mexico: a single hospital-based study in a 20-year period (1987–2006)J Clin Gastroenterol20094322122419057395
   PubMed Web of Science ®Google Scholar
• NgSCTangWChingJYIncidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology studyGastroenterology201314515816523583432
   PubMed Web of Science ®Google Scholar
• ParenteJMCoyCSCampeloVInflammatory bowel disease in an underdeveloped region of Northeastern BrazilWorld J Gastroenterol2015211197120625632193
   PubMed Web of Science ®Google Scholar
• SilverbergMSSatsangiJAhmadTToward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of GastroenterologyCan J Gastroenterol200519Suppl A5A36A
   PubMed Web of Science ®Google Scholar
• GerichMEMcGovernDPTowards personalized care in IBDNat Rev Gastroenterol Hepatol20141128729924345887
   PubMed Web of Science ®Google Scholar
• Yamamoto-FurushoJKFonseca-CamarilloGGenetic markers associated with clinical outcomes in patients with inflammatory bowel diseaseInflamm Bowel Dis2015212683269526244649
   PubMed Web of Science ®Google Scholar
• QuetglasEGMujagicZWiggeSUpdate on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel diseaseWorld J Gastroenterol201521125191254326640330
   PubMed Web of Science ®Google Scholar
• KirchheinerJFuhrUBrockmöllerJPharmacogenetics-based therapeutic recommendations – ready for clinical practice?Nat Rev Drug Discov2005463964716056390
   PubMed Web of Science ®Google Scholar
• KatsanosKHPapadakisKAPharmacogenetics of inflammatory bowel diseasePharmacogenomics2014152049206225521361
   PubMed Web of Science ®Google Scholar
• LawsonMMThomasAGAkobengAKTumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis [review]Cochrane Database Syst Rev20063CD005112
   Google Scholar
• Yamamoto-FurushoJKPeñaloza-CoronelASánchez-MuñozFBarreto-ZúñigaRDomínguez-LópezAPeroxisome proliferator-activated receptor-gamma (PPAR gamma) expression is downregulated in patients with active ulcerative colitisInflamm Bowel Dis20111768068120848495
   PubMed Web of Science ®Google Scholar
• Yamamoto-FurushoJKJacintez-CazaresMFuruzawa-CarballedaJFonseca-CamarilloGPeroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitisDis Markers2014201493253025548431
   PubMed Web of Science ®Google Scholar
• ProhászkaZFüstGImmunological aspects of heat-shock proteins – the optimum stress of lifeMol Immunol200441294415140573
   PubMed Web of Science ®Google Scholar
• RodolicoVTomaselloGZerilliMHsp60 and Hsp10 increase in colon mucosa of Crohn’s disease and ulcerative colitisCell Stress Chaperones20101587788420390473
   PubMed Web of Science ®Google Scholar
• TomaselloGRodolicoVZerilliMChanges in immunohistochemical levels and subcellular localization after therapy and correlation and colocalization with CD68 suggest a pathogenetic role of Hsp60 in ulcerative colitisAppl Immunohistochem Mol Morphol20111955256121441812
   PubMedGoogle Scholar
• TomaselloGSciuméCRappaFHsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapyEur J Histochem201155e3822297444
   PubMed Web of Science ®Google Scholar
• GabryelMSkrzypczak-ZielinskaMKucharskiMASlomskiRDobrowolskaAThe impact of genetic factors on response to glucocorticoids therapy in IBDScand J Gastroenterol20165165466526776488
   PubMed Web of Science ®Google Scholar
• AnneseVValvanoMRPalmieriOMultidrug resistance 1 gene in inflammatory bowel disease: a meta-analysisWorld J Gastroenterol2006123636364416773678
   PubMed Web of Science ®Google Scholar
• FarrellRJMurphyALongAHigh multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapyGastroenterology200011827928810648456
   PubMed Web of Science ®Google Scholar
• Yamamoto-FurushoJKVilleda-RamírezMAFonseca-CamarilloGHigh gene expression of MDR1 (ABCB1) is associated with medical treatment response and long term remission in patients with ulcerative colitisInflamm Bowel Dis20101654171919714749
   PubMed Web of Science ®Google Scholar
• HondaMOriiFAyabeTExpression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitisGastroenterology200011885986610784585
   PubMed Web of Science ®Google Scholar
• FujishimaSTakedaHKawataSYamakawaMThe relationship between the expression of the glucocorticoid receptor in biopsied colonic mucosa and the glucocorticoid responsiveness of ulcerative colitis patientsClin Immunol200913320821719646928
   PubMed Web of Science ®Google Scholar
• Yamamoto-FurushoJKSantiago-HernándezJJPérez-HernándezNRamírez-FuentesSFragosoJMVargas-AlarcónGInterleukin 1β (IL-1B) and IL-1 antagonist receptor (IL-1RN) gene polymorphisms are associated with the genetic susceptibility and steroid dependence in patients with ulcerative colitisJ Clin Gastroenterol20114553153520975573
   PubMed Web of Science ®Google Scholar
• Montero-MeléndezTLlorXGarcía-PlanellaEPerrettiMSuárezAIdentification of novel predictor classifiers for inflammatory bowel disease by gene expression profilingPLoS One20138e7623524155895
   PubMed Web of Science ®Google Scholar
• Villeda RamírezMAMendivil RangelEJDomínguez LópezAYamamoto-FurushoJKInterleukin-18 upregulation is associated with the use of steroids in patients with ulcerative colitisInflamm Bowel Dis201117E50E5121456035
   PubMed Web of Science ®Google Scholar
• DubinskyMCAzathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safetyClin Gastroenterol Hepatol2004273174315354273
   PubMed Web of Science ®Google Scholar
• SchaeffelerELangTZangerUMEichelbaumMSchwabMHigh-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLCClin Chem20014754855511238310
   PubMed Web of Science ®Google Scholar
• SchaeffelerEFischerCBrockmeierDComprehensive analysis of thiopurine S-methyltransferase phenotype–genotype correlation in a large population of German-Caucasians and identification of novel TPMT variantsPharmacogenetics20041440741715226673
   PubMedGoogle Scholar
• ReutherLOSonneJLarsenNDahlerupJFThomsenOOSchmiegelowKThiopurine methyltransferase genotype distribution in patients with Crohn’s diseaseAliment Pharmacol Ther200317656812492733
   PubMed Web of Science ®Google Scholar
• YatesCRKrynetskiEYLoennechenTMolecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intoleranceAnn Intern Med19971266086149103127
   PubMed Web of Science ®Google Scholar
• AnsariAHassanCDuleyJThiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel diseaseAliment Pharmacol Ther2002161743175012269967
   PubMed Web of Science ®Google Scholar
• KurzawskiMGawronska-SzklarzBDrozdzikMFrequency distribution of thiopurine S-methyltransferase alleles in a Polish populationTher Drug Monit20042654154515385838
   PubMed Web of Science ®Google Scholar
• KubotaTChibaKFrequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositusBr J Clin Pharmacol20015147547711422006
   PubMed Web of Science ®Google Scholar
• AmeyawMMCollie-DuguidESPowrieRHOfori-AdjeiDMcLeodHLThiopurine methyltransferase alleles in British and Ghanaian populationsHum Mol Genet199983673709931345
   PubMed Web of Science ®Google Scholar
• HeapGAWeedonMNBewsheaCMHLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressantsNat Genet2014461131113425217962
   PubMed Web of Science ®Google Scholar
• LennardLTPMT in the treatment of Crohn’s disease with azathioprineGut20025114314612117866
   PubMed Web of Science ®Google Scholar
• DubinskyMCLamotheSYangHYPharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel diseaseGastroenterology200011870571310734022
   PubMed Web of Science ®Google Scholar
• WeinshilboumRMSladekSLMercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activityAm J Hum Genet1980326516627191632
   PubMed Web of Science ®Google Scholar
• MoonWLoftusEVJrReview article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel diseaseAliment Pharmacol Ther Epub2016214
   Web of Science ®Google Scholar
• FongSCBlakerPAArenas-HernandezMMarinakiAMSandersonJDGetting the best out of thiopurine therapy: thiopurine S-methyltransferase and beyondBiomark Med20159516525605455
   PubMed Web of Science ®Google Scholar
• StoccoGPelinMFrancaRPharmacogenetics of azathioprine in inflammatory bowel disease: a role for glutathione-S-transferase?World J Gastroenterol2014203534354124707136
   PubMed Web of Science ®Google Scholar
• StoccoGMartelossiSBarabinoAGlutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel diseaseInflamm Bowel Dis200713576417206640
   PubMed Web of Science ®Google Scholar
• DervieuxTBoulieuRSimultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLCClin Chem1998445515559510860
   PubMed Web of Science ®Google Scholar
• StoccoGCuzzoniEDe IudicibusSDeletion of glutathione-S-transferase M1 reduces azathioprine metabolite concentrations in young patients with inflammatory bowel diseaseJ Clin Gastroenterol201448435123787247
   PubMed Web of Science ®Google Scholar
• DubinskyMCLamotheSYangHYPharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel diseaseGastroenterology200011870571310734022
   PubMed Web of Science ®Google Scholar
• OstermanMTKunduRLichtensteinGRLewisJDAssociation of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysisGastroenterology20061301047105316618398
   PubMed Web of Science ®Google Scholar
• HindorfULindqvistMHildebrandHFagerbergUAlmerSAdverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel diseaseAliment Pharmacol Ther20062433134216842460
   PubMed Web of Science ®Google Scholar
• YarurAJAbreuMTDeshpandeARKermanDHSussmanDATherapeutic drug monitoring in patients with inflammatory bowel diseaseWorld J Gastroenterol2014203475348424707130
   PubMed Web of Science ®Google Scholar
• Prieto-PérezRAlmogueraBCabaleiroTHakonarsonHAbad-SantosFAssociation between genetic polymorphisms and response to anti-TNFs in patients with inflammatory bowel diseaseInt J Mol Sci20161722526861312
   PubMed Web of Science ®Google Scholar
• HlavatyTPierikMHenckaertsLPolymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn’s diseaseAliment Pharmacol Ther20052261362616181301
   PubMed Web of Science ®Google Scholar
• MoroiREndoKKinouchiYFCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activityImmunogenetics20136526527123358932
   PubMed Web of Science ®Google Scholar
• KoderSRepnikKFerkoljIGenetic polymorphism in ATG16l1 gene influences the response to adalimumab in Crohn’s disease patientsPharmacogenomics20151619120425712183
   PubMed Web of Science ®Google Scholar
• JürgensMLaubenderRPHartlFDisease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitisAm J Gastroenterol20101051811181920197757
   PubMed Web of Science ®Google Scholar
• BankSAndersenPSBurischJAssociations between functional polymorphisms in the NFB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel diseasePharmacogenom J201414526534
   PubMed Web of Science ®Google Scholar
• FujinoSAndohABambaSIncreased expression of interleukin 17 in inflammatory bowel diseaseGut2013526570
   Web of Science ®Google Scholar
• AfifWLoftusEVJrFaubionWAClinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel diseaseAm J Gastroenterol20101051133113920145610
   PubMed Web of Science ®Google Scholar
• BortlikMDuricovaDMalickovaKInfliximab trough levels may predict sustained response to infliximab in patients with Crohn’s diseaseJ Crohns Colitis2013773674323200919
   PubMed Web of Science ®Google Scholar
• Van MoerkerckeWAckaertCCompernolleGHigh infliximab trough levels are associated with mucosal healing in Crohn’s diseaseGastroenterology2010138S60
   Web of Science ®Google Scholar
• BaertFNomanMVermeireSInfluence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseN Engl J Med200334860160812584368
   PubMed Web of Science ®Google Scholar
• RoblinXMarotteHRinaudoMAssociation between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseasesClin Gastroenterol Hepatol201412808423891927
   PubMed Web of Science ®Google Scholar
• YarurAJJainAHauensteinSIHigher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn’s disease and ulcerative colitisInflamm Bowel Dis20162240941526752470
   PubMed Web of Science ®Google Scholar
• SeowCHNewmanAIrwinSPSteinhartAHSilverbergMSGreenbergGRTrough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitisGut201059495419651627
   PubMed Web of Science ®Google Scholar
• KarmirisKPaintaudGNomanMInfluence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s diseaseGastroenterology20091371628164019664627
   PubMed Web of Science ®Google Scholar
• NandaKSCheifetzASMossACImpact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysisAm J Gastroenterol2013108404723147525
   PubMed Web of Science ®Google Scholar
• VelayosFSSheibaniSLocktonSPrevalence of antibodies to adalimumab (ATA) and correlation between ATA and low serum drug concentration on CRP and clinical symptoms in a prospective sample of IBD patientsGastroenterology2013144S91
   Web of Science ®Google Scholar
• TewGWHackneyJAGibbonsDAssociation between response to etrolizumab and expression of integrin αE and granzyme A in colon biopsies of patients with ulcerative colitisGastroenterology201615047748726522261
   PubMed Web of Science ®Google Scholar
• SwidsinskiALadhoffAPernthalerAMucosal flora in inflammatory bowel diseaseGastroenterology2002122445411781279
   PubMed Web of Science ®Google Scholar
• PhilpottDJGirardinSECrohn’s disease-associated Nod2 mutants reduce IL10 transcriptionNat Immunol20091045545719381138
   PubMed Web of Science ®Google Scholar
• FrankDNRobertsonCEHammCMDisease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseasesInflamm Bowel Dis20111717918420839241
   PubMed Web of Science ®Google Scholar
• RauschPRehmanAKunzelSColonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (secretor) genotypeProc Natl Acad Sci U S A2011108190301903522068912
   PubMed Web of Science ®Google Scholar
• LuppCRobertsonMLWickhamMEHost-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of EnterobacteriaceaeCell Host Microbe2007211912918005726
   PubMed Web of Science ®Google Scholar
• Darfeuille-MichaudABoudeauJBuloisPHigh prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s diseaseGastroenterology200412741242115300573
   PubMed Web of Science ®Google Scholar
• SokolHLepagePSeksikPDoreJMarteauPTemperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitisJ Clin Microbiol2006443172317716954244
   PubMed Web of Science ®Google Scholar
• OhkusaTSatoNOgiharaTMoritaKOgawaMOkayasuIFusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibodyJ Gastroenterol Hepatol20021784985312164960
   PubMed Web of Science ®Google Scholar
• OhkusaTYoshidaTSatoNWatanabeSTajiriHOkayasuICommensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitisJ Med Microbiol20095853554519369513
   PubMed Web of Science ®Google Scholar
• AtarashiKTanoueTOshimaKTreg induction by a rationally selected mixture of Clostridia strains from the human microbiotaNature201350023223623842501
   PubMed Web of Science ®Google Scholar
• LlopisMAntolinMCarolMLactobacillus casei downregulates commensals’ inflammatory signals in Crohn’s disease mucosaInflamm Bowel Dis20091527528318839424
   PubMed Web of Science ®Google Scholar
• SokolHPigneurBWatterlotLFaecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patientsProc Natl Acad Sci U S A2008105167311673618936492
   PubMed Web of Science ®Google Scholar
• WillingBHalfvarsonJDicksvedJTwin studies reveal specific imbalances in the mucosa associated microbiota of patients with ileal Crohn’s diseaseInflamm Bowel Dis20091565366019023901
   PubMed Web of Science ®Google Scholar
• VarelaEManichanhCGallartMColonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitisAliment Pharmacol Ther20133815116123725320
   PubMed Web of Science ®Google Scholar
• PascalVPozueloMBorruelNA microbial signature for Crohn’s diseaseGut201766581382228179361
   PubMed Web of Science ®Google Scholar
• MoayyediPSuretteMGKimPTFecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trialGastroenterology20151102109
   Web of Science ®Google Scholar
• RossenNGFuentesSvan der SpekMJFindings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitisGastroenterology20151110118
   Web of Science ®Google Scholar